Idiotypic Vaccination for Poor-prognosis Follicular Lymphoma Patients in First Relapse
Idiotypic vaccination has already proved capable (in responding patients) of: biological
efficacy, that is the capacity of inducing an idiotype- and tumor-specific immune response
(Kwak LW et al. NEJM 1992); clinical efficacy, that is the capacity of inducing specific
immune responses able to kill in vivo follicular lymphoma cells that had survived
pre-vaccine chemotherapy (Bendandi M et al. Nature Med 1999): clinical benefit, that is the
capacity of prolonging survival of responding patients (Inoges et al. JNCI 2006). Now, we
want to test whether it is also capable of contributing to the ultimate goal of preventing
relapse indefinitely in responding patients.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Percentage of patients who both never relapse and have a second complete response longer than their first response (cured)
15 years
No
MAURIZIO BENDANDI, MD, PhD
Principal Investigator
University of Navarra
Spain: Ministry of Health
CUN-90-2006
NCT00530140
October 2007
September 2022
Name | Location |
---|